{"id":560817,"date":"2026-07-03T01:00:00","date_gmt":"2026-07-02T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/tirzepatide-versus-dulaglutide-dans-le-dt2-associe-a-une-ascvd\/"},"modified":"2026-07-10T17:57:42","modified_gmt":"2026-07-10T15:57:42","slug":"tirzepatide-versus-dulaglutide-dans-le-dt2-associe-a-une-ascvd","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/tirzepatide-versus-dulaglutide-dans-le-dt2-associe-a-une-ascvd\/","title":{"rendered":"Tirz\u00e9patide versus dulaglutide dans le DT2 associ\u00e9 \u00e0 une ASCVD"},"content":{"rendered":"\n

Les agonistes des r\u00e9cepteurs du GLP-1 se sont impos\u00e9s ces derni\u00e8res ann\u00e9es comme une classe de substances \u00e0 effet cardioprotecteur dans le diab\u00e8te de type 2. Concernant le dulaglutide, l\u2019\u00e9tude REWIND de 2019 a d\u00e9montr\u00e9 que cette substance r\u00e9duisait les \u00e9v\u00e9nements cardiovasculaires graves par rapport au placebo \u2013 sur une dur\u00e9e m\u00e9diane d\u2019observation de 5,4 ans, environ un tiers des participants pr\u00e9sentant une maladie cardiovasculaire av\u00e9r\u00e9e et les autres des facteurs de risque cardiovasculaires. Le tirz\u00e9patide, un agoniste double des r\u00e9cepteurs du GLP-1 et du GIP, avait montr\u00e9, lors des \u00e9tudes d\u2019enregistrement (programme SURPASS), un effet marqu\u00e9 sur la glyc\u00e9mie et le poids corporel. Il manquait toutefois une preuve directe d\u2019un b\u00e9n\u00e9fice cardiovasculaire dans une \u00e9tude de r\u00e9sultats sp\u00e9cialement con\u00e7ue \u00e0 cet effet. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Les agonistes des r\u00e9cepteurs du GLP-1 se sont impos\u00e9s ces derni\u00e8res ann\u00e9es comme une classe de substances \u00e0 effet cardioprotecteur dans le diab\u00e8te de type 2. Concernant le dulaglutide, l\u2019\u00e9tude……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560820,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"SURPASS-CVOT","footnotes":""},"category":[11549,11378,11404,11527,11531,11315,11464],"tags":[21342,72440],"powerkit_post_featured":[],"class_list":["post-560817","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-cardiologie","category-endocrinologie-et-diabetologie","category-etudes","category-formation-continue","category-medecine-interne-generale","category-pharmacologie-et-toxicologie","tag-dulaglutide-fr","tag-tirzepatide-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-20 12:13:57","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":560822,"slug":"tirzepatide-rispetto-a-dulaglutide-nel-diabete-di-tipo-2-con-ascvd","post_title":"Tirzepatide rispetto a dulaglutide nel diabete di tipo 2 con ASCVD","href":"https:\/\/medizinonline.com\/it\/tirzepatide-rispetto-a-dulaglutide-nel-diabete-di-tipo-2-con-ascvd\/"},"pt_PT":{"locale":"pt_PT","id":560827,"slug":"tirzepatida-versus-dulaglutida-na-diabetes-tipo-2-com-ascvd","post_title":"Tirzepatida versus dulaglutida na diabetes tipo 2 com ASCVD","href":"https:\/\/medizinonline.com\/pt-pt\/tirzepatida-versus-dulaglutida-na-diabetes-tipo-2-com-ascvd\/"},"es_ES":{"locale":"es_ES","id":560833,"slug":"tirzepatida-frente-a-dulaglutida-en-la-diabetes-tipo-2-con-ascvd","post_title":"Tirzepatida frente a dulaglutida en la diabetes tipo 2 con ASCVD","href":"https:\/\/medizinonline.com\/es\/tirzepatida-frente-a-dulaglutida-en-la-diabetes-tipo-2-con-ascvd\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/560817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=560817"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/560817\/revisions"}],"predecessor-version":[{"id":560821,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/560817\/revisions\/560821"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/560820"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=560817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=560817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=560817"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=560817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}